Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.32 USD
Change Today -0.79 / -25.40%
Volume 2.2M
DSKX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

ds healthcare group inc (DSKX) Snapshot

Open
$3.01
Previous Close
$3.11
Day High
$3.07
Day Low
$2.27
52 Week High
06/19/15 - $4.96
52 Week Low
12/22/14 - $0.56
Market Cap
39.7M
Average Volume 10 Days
1.2M
EPS TTM
$-0.04
Shares Outstanding
17.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DS HEALTHCARE GROUP INC (DSKX)

Related News

No related news articles were found.

ds healthcare group inc (DSKX) Related Businessweek News

No Related Businessweek News Found

ds healthcare group inc (DSKX) Details

DS Healthcare Group, Inc., doing business as DS Laboratories, develops and markets hair care, skin care, and personal care products in North America and internationally. Its hair care products include Revita and Revita LT shampoos, and Revita.Cor conditioner for hair growth stimulation; Dandrene, an antifungal shampoo to treat itchy scalp and dandruff; and Spectral line of products comprising Spectral.DNC spray formula, Spectral.DNC-L lotion, and Spectral DNC-N to re-grow hair through various pathways, as well as Spectral.RS, a topical treatment for men and women with advanced androgenic alopecia. The company’s skin care products comprise Hydroviton, a skin cleanser for oily and acne prone skin; Keramene, which is used to suppress hair growth and soften remaining hair strands; Oligo.DX, a cream to enhance the appearance of cellulite from women’s thighs, hips, and buttocks; and Trioxil, an acne cream. Its personal care products consist of Nirena, an intimate feminine care cleanser; and Spectral Lash, a product based on advanced bio-peptides that are designed to grow and enhance the length and girth of eyelash hair. DS Healthcare Group, Inc. markets and sells its products under the DS Laboratories, Polaris Labs, and Sigma Skin brands through salons, spas, department stores, specialty retailers, and distributors. The company was formerly known as Divine Skin, Inc. and changed its name to DS Healthcare Group, Inc. in November 2012. DS Healthcare Group, Inc. is headquartered in Pompano Beach, Florida.

46 Employees
Last Reported Date: 04/15/15

ds healthcare group inc (DSKX) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2014.

ds healthcare group inc (DSKX) Key Developments

DS Healthcare Group, Inc. Finalizes a Distribution Agreement in Egypt with MultiTrade

DS Healthcare Group, Inc. announced it has finalized a distribution agreement in Egypt with MultiTrade. MultiTrade has placed orders for immediate delivery to begin supplying customers in the region.

DS Healthcare Group, Inc. Reveals its Over-the-Counter Tablet, Integra, for Thinning Hair and Improved Hair Health

DS Healthcare Group, Inc.'s Integra over-the-counter tablet for thinning hair and improved hair health is now here. It is the first tablet that contains Astressin-B along with a combination of other novel compounds. This product is the result of findings from DS Healthcare Groups ongoing research on hair loss and related conditions. Astressin-B is a complex peptide that has shown in landmark research that it can reduce the effects of Corticotropin-releasing hormone (CRH) involved in the stress response. CRH is associated with many other diseases and is also believed to have a direct impact on hair health.

Ds Healthcare Group, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

DS Healthcare Group, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported GAAP net loss of $85,138 compared to $850,153 a year ago. Adjusted EBITDAS was $48,492 compared to adjusted LBITDAS of $786,845 a year ago. Net revenues were $2,803,920 up 4.4% over first quarter of 2014. Revenue growth in the first quarter was driven by higher demand for the company products both in the US and internationally.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSKX:US $2.32 USD -0.79

DSKX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $97.68 USD -1.96
Procter & Gamble Co/The $78.32 USD -1.02
View Industry Companies
 

Industry Analysis

DSKX

Industry Average

Valuation DSKX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DS HEALTHCARE GROUP INC, please visit www.dslaboratories.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.